Julia Shapiro

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.

Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.

Journal: Journal of geriatric oncology

Published: April 11, 2023

Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.

Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.

Journal: British journal of cancer

Published: January 26, 2023

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Journal: Expert review of pharmacoeconomics & outcomes research

Published: December 21, 2022

Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer.

Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer.

Journal: BJU international

Published: November 13, 2022

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.

Journal: European urology

Published: May 19, 2022

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 20, 2022

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.

Journal: BJU international

Published: October 08, 2021

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.

Journal: BJUI compass

Published: August 02, 2021

Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.

Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.

Journal: Asia-Pacific journal of clinical oncology

Published: May 16, 2021

Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals.

Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals.

Journal: Asia-Pacific journal of clinical oncology

Published: May 10, 2021

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 02, 2021

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.

Journal: Asia-Pacific journal of clinical oncology

Published: May 17, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026